argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)

Continue reading here:
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Related Posts